期刊文献+

卡培他滨单药节拍化治疗老年晚期胃癌21例疗效观察 被引量:18

The efficacy of Capecitabine in metronomic treatment for elderly advanced gastric cancer in 21 cases
在线阅读 下载PDF
导出
摘要 目的探讨卡培他滨小剂量、高频率、持续性给药治疗老年晚期胃癌的疗效。方法将42例临床IV期胃癌患者分为对照组和观察组:对照组采用XELOX化疗方案,观察组采用卡培他滨节拍化疗方案。两组均给予2个周期的化疗和对症支持治疗用药:维生素C,维生素B6,地塞米松、西米替丁、阿扎司琼、胃复安、粒细胞集落刺激因子等。结果对照组CR为9.52%,PR为57.41%,SD为19.05%,PD为14.29%,RR为66.67%,止痛药减少者57.89%,疼痛减轻者42.11%,KPS改善者61.90%,体重增加者28.57%,不良反应发生率为204.76%;观察组CR为14.29%,PR为52.38%,SD为23.81%,PD为9.52%,RR为66.67%,止痛药减少者85.0%,疼痛减轻者15.0%,KPS改善者76.19%,体重增加者42.86%,不良反应发生率为133.33%。结论卡培他滨单药节拍化治疗用于老年晚期胃癌患者,不良反应少,疗效和临床受益与XELOX化疗方案用药无差异。 Objective To investigate the efficacy of capecitabine with low dose,high frequency and continuous infusion in treatment of elderly advanced gastric cancer.Method Forty patients with stage IV gastric cancer patients were divided into control group and observation group:control group were received XELOX chemotherapy regimen,and the observation group were received capecitabine metronomic chemotherapy.Both groups were given two courses chemotherapies,symptomatic and supportive therapeutic drugs:vitamin C,vitamin B6,dexamethasone,cimetidine,Azasetron,metoclopramide,granulocyte colonystimulating factor et al.Results In control group,CR was 9.52%,PR 57.41%,SD 19.05%,PD 14.29%,RR 66.67%,less painkillers 57.89%,and pain relief were 42.11%,KPS improved 61.90%,weight increased 28.57%,incidence of adverse reactions 204.76%;and in the observation group CR 14.29%,PR 52.38%,SD 23.81%,PD 9.52%,RR 66.67%,less pain medication 85.0%,and pain relief were 15.0%,KPS improved 76.19%,weight increased 42.86%,incidence of adverse reactions was 133.33%.Conclusion Capecitabine metronomic chemotherapy in the treatment for elderly patients with advanced gastric cancer can make less adverse reactions and similar efficacy and clinical benefit to the XELOX regimen.
作者 彭若飞
出处 《肿瘤药学》 CAS 2011年第6期514-517,共4页 Anti-Tumor Pharmacy
关键词 胃癌 卡培他滨 疗效 节拍化疗 Gastric cancer Capecitabine Efficacy Metronomic chemotherapy
  • 相关文献

参考文献7

二级参考文献50

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2沈琳,李洁,张晓东,李燕,张小田,金懋林.PELF方案治疗进展期胃癌68例[J].中国肿瘤临床,2005,32(3):162-164. 被引量:19
  • 3范若兰.我国肺癌流行病学研究及病因研究概况[J].中国肿瘤,1993,2(11):3-9. 被引量:41
  • 4Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a ran- domized muhicentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cis- platin in patients with advanced oesophagogastric cancer receiving ECF[J]. Br J Cancer, 2005, 92(11).. 1976-1983.
  • 5Oh DY,Kim TY,Kwon JH,et al. Docetaxel+5-fluorouracil+ cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer [J]. Jpn J Clin Oncol, 2005, 35(7): 380-385.
  • 6Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group[J]. J Clin Oncol, 2006, 24(31):4991-4997.
  • 7[1]Sasaki T,Maeda Y,Kobayashi T,et al.Standard chemotherapy for gastrointestinal malignancies based on evidence.Jap J Cancer Chemother,2000,27 (20):166
  • 8[4]Jin M,Shen L,Hu B,et al.Mature data on capecitabine (X) + fractionated cisplatin (P) as first-line therapy in patients (pts) with advanced gastric carcinoma (AGC).Proc Am Soc Clin Oncol,2006,24:196S
  • 9[5]Kang Y,Kang WK,Shin DB,et al.Randomized phase Ⅲtrial of capecitabine/cisplatin (XP) vs continuous infusion of 5 -FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):Efficacy and safety results.Proc Am Soc Clin Oncol,2006,24:183S
  • 10[6]Shitara K,Sakata Y,Kudou T,et al.Gastric Cancer:S -1 monotherapy and its progress.Jpn J Cancer Chemother,2006,33 (Suppl I):43

共引文献359

同被引文献162

引证文献18

二级引证文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部